| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
6 companies
Bienaime Jean Jacques serves as a Director at BMRN and has filed Form 4s across 6 companies. Across recent SEC filings that breaks down to 32 buys and 186 sells. Those positions are worth an estimated $38.3M at current prices.
Historically, Bienaime Jean Jacques's trades have earned a middling insider score of 68/100 across 67 rated trades. Over a 12-month horizon, 64.3% of those trades were profitable, with an average 12-month return of +8.5%.
The biggest single holding is BMRN (~$36.5M) as Director. The recent filings there lean toward selling, a net 2,115,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | KROS Keros Therapeutics, Inc. | Director | Buy10b5-1 | 1,000 | $10.27 | $10,270.00 | +5.4% | - | - | |
| Aug 14, 2026 | ASND Ascendis Pharma A/s | Director | Buy | 2,000 | $246.33 | $492,654.00 | +222.2% | - | - | |
| Jul 15, 2026 | KROS Keros Therapeutics, Inc. | Director | Buy10b5-1 | 1,000 | $10.61 | $10,610.00 | +5.7% | +1.8% | - | |
| Jun 15, 2026 | KROS Keros Therapeutics, Inc. | Director | Buy10b5-1 | 1,000 | $10.19 | $10,190.00 | +6.0% | +9.5% | - | |
| Jun 5, 2026 | IMNM Immunome, Inc. | Director | Sell | 10,500 | $19.41 | $203,820.00 | -24.2% | +46.2% | - | |
| Jun 5, 2026 | IMNM Immunome, Inc. | Director | Buy | 10,500 | $19.45 | $204,260.00 | +31.9% | +46.2% | - | |
| May 29, 2026 | ASND Ascendis Pharma A/s | Director | Buy | 500 | $223.12 | $111,562.00 | +125.0% | +11.3% | - | |
| May 26, 2026 | ASND Ascendis Pharma A/s | Director | Buy | 400 | $237.80 | $95,120.50 | New | +5.1% | - | |
| May 15, 2026 | IMNM Immunome, Inc. | Director | Buy | 5,000 | $20.70 | $103,500.00 | +13.0% | +26.5% | - | |
| May 15, 2026 | KROS Keros Therapeutics, Inc. | Director | Buy10b5-1 | 1,000 | $10.58 | $10,580.00 | +11.8% | +1.5% | - |